
Poly Medicure Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Company targets domestic revenue close to INR 500 crores by year-end with ~500 sales associates.
- Sales productivity per rep targeted at around INR 1 crore annually on a blended basis.
- Plans to add about 100 new sales associates in FY25; expects to double headcount over next 3-4 years to reach nearly 20,000 hospitals (from current 8,000-9,000).
- Expects 20% annual growth rate that will double the business size in 4 years.
- Renal business is growing at 50%+ and is expected to constitute 25-28% of total India business soon.
- European exports anticipated to grow ~30-35% in coming years; overall export growth guidance is 25-27%.
- U.S. business to grow with FDA approvals; first-year revenue expected at USD 2-3 million, with a 3-4 year target of USD 15-20 million.
- New plants equipped to double capacity in core segments like renal dialysis by FY26.
- Domestic business growth expected at ~20% yearly; maintains cautious margin guidance due to geopolitical uncertainties.
See what Poly Medicure management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company raised funds through a Qualified Institutional Placement (QIP) amounting to around INR 1,000 crores in the previous quarter.
- Out of the QIP proceeds, INR 500 crores are allocated for new capex, INR 250 crores for general corporate purposes including working capital and acquisitions.
- The company currently has around INR 250 crores of cash surplus, which will also be deployed in these areas.
- Capex spending of INR 150 crores has already been done from internal accruals in the current 6 months; no QIP money has been used so far for this.
- Further capex of INR 100 crores to INR 125 crores will be spent in the next 6 months from internal accruals.
- No mention of new or planned fundraising through additional debt or equity beyond this QIP and internal accrual utilization was provided.
See what Poly Medicure management said on order book — free account, 30 seconds.
Capex plans
Yes- Poly Medicure has planned a capex of INR 500 crores funded mainly through QIP proceeds for setting up three new plants in Haryana, Rajasthan, and Uttarakhand.
- These new facilities are expected to be operational by mid to end of FY 2026.
- Current capex includes INR 150 crores already spent in the first 6 months of FY 2025 from internal accruals on existing plants for automation and capacity expansion.
- Additional capex of INR 100-125 crores is planned in the remaining FY 2025 for adding machines and capacity in current plants.
- The new plants will double renal dialysis capacity in the next 2 years and expand product capacities in cardiology and critical care.
- INR 250 crores from QIP are earmarked for acquisitions in adjacent therapy areas to accelerate growth via technology and regulatory clearances.
- The company also has about INR 250 crores cash surplus for further investments.
Track Poly Medicure — get its next earnings analysis in your feed
How does Poly Medicure rank vs peers in Healthcare Equipment & Supplies?
Pro featureHow does Poly Medicure rank in Healthcare Equipment & Supplies?
Compare Poly Medicure against every Healthcare Equipment & Supplies company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Poly Medicure's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Fischer Medical (Q2 FY27)
For the quarter ended September 30, 2026, the Standalone revenue from operations was ₹27.62 Lakhs compared to ₹742.69 Lakhs in Q2 FY 2025, showing a…
- Mohini Health (Q2 FY27)
Revenue from operations for the half year ended 30th Sept 2026 is ₹11,043.00 lakhs, compared to ₹7,353.87 lakhs for the half year ended 30th Sept 2025, showing…
- Aprameya Enginee (Q2 FY27)
216.21 lakhs, up 97% year-on-year (YoY). Key results statement takeaways from Aprameya Engineering Ltd's Q2 FY27 results statement — and how it ranks against se
- QMS Medical (Q2 FY27)
4,470.00 lakhs in Q2 2025), a year-on-year increase of approximately 17.5% . Key results statement takeaways from QMS Medical Allied Services Ltd's Q2 FY27 resu